Day Two

Explore the Agenda

New Frontiers & Mechanisitc Day

Monday, October 27

Industry Day One

Tuesday, October 28

Industry Day Two

Wednesday, October 29

Future of Induced Proximity Day

Thursday, October 30

7:30 am Check-In & Morning Coffee

8:20 am Chair’s Opening Remarks

Lawrence Hamann

Co-founder, President and CEO, Interdict Bio

Navigating the Evolving TPD Landscape to Understand Future Directions & Drive the Next-Generation of Proximity Therapeutics

8:30 am Panel Discussion: The TPD Investment Landscape: Lessons from Deals in 2025 & Expectations for 2026

Christopher O’Donnell

Executive Director & Vice President - Business Development, Emerging Sciences & Innovation, Partner, Pfizer

Lawrence Hamann

Co-founder, President and CEO, Interdict Bio

Anna Rivkin

Chief Business Officer, Foghorn Therapeutics

Xiaoqi Liu

Senior Director, Head of Business Development & Strategic Finance, Degron Therapeutics

Takeru Furuya

Principal, Perceptive Advisors LLC

Aly Jackson

Business Development Project Leader, Pharma Partnering, Genentech

Neil Torbett

Chief Executive Officer, PhoreMost

Download the Full Event Guide for Full Session Details.

9:15 am Discovery of a VHL-Based Molecular Glue Degrader Targeting GEMIN3 Using Picowell RNA-Sequencing

Ryan Potts

Vice President, Amgen Inc.

Download the Full Event Guide for Full Session Details.

9:45 am Illuminating New Insights in Targeted Protein Degradation Kinetics, Mechanisms, & Selectivity

Kristin Riching

R&D Group Leader, Promega Corporation

Download the Full Event Guide for Full Session Details.

10:15 am Expanding Targeted Glue Applications by Recruiting Novel E3 Ligases Across Diverse Targets

Louise Modis

Chief Scientific Officer, Amphista Therapeutics

Download the Full Event Guide for Full Session Details.

10:45 am Morning Break & Networking

Track A: Discovery Track B: Pre-Clinical Development Track C: Translational & Clinical Development

Track A: Discovery

Accelerating Molecular Glue Innovation Through Structure-Guided Design & Empirical Discovery to Enable Selective Targeting & Unlock New Therapeutic Opportunities

11:30 am Structure-Based Development of Non-Degrader Molecular Glues to Selectively Stabilize a Tumor Suppressor Phosphatase Complex

Derek Taylor

Head of Structural Biology (Rappta Therapeutics); Professor (Case Western Reserve University), Case Western Reserve University

Download the Full Event Guide for Full Session Details.

12:00 pm K-RAS Molecular Glue Degraders

Abdulsalam Shaaban

Vice President, Research and Development, Lifesensors

12:30 pm Building A Computational Design Platform For Any Molecular Glue

Chris Tame

Chief Executive Officer, Ternary Therapeutics

Discussing the requirements of a successful molecular glue design platform
Blending the speed and scalability of Machine Learning with the accuracy of Physics-Based Methods for optimal protein-protein matching and ternary complex structure prediction
Computational design and experimental validation of optimised molecular glue degraders and activators

Track B: Pre-Clinical Development

Advancing Innovative Strategies Targeting KRAS & EGFR with Integrated Degraders & Molecular Glues to Overcome Resistance & Enhance Therapeutic Efficacy

11:30 am Optimizing EGFR & KRAS G12D Targeting: Polymed’s Integrated Approach to PROTACs & DACs

Brent Meadows

Chief Business Officer, Polymed Biopharmaceuticals

Download the Full Event Guide for Full Session Details.

12:00 pm Uncovering a Dual Molecular Glue Degrader for KRAS Mutants & CRAF: Harnessing Novel E3 Ligase-Mediated Targeted Protein Degradation

Anita Bellail

co-CEO, HB Therapeutics, Inc.

Download the Full Event Guide for Full Session Details.

Track C: Translational & Clinical Development

Advancing First-in-Class Tau Aggregate Degradation and Lipid Kinase Targeting to Accelerate Therapeutics in Neurodegeneration & Oncology

11:30 am Orally Bioavailable NRF2 Molecular Glue Degrader Effective in KEAP1-Mutant Cancer

Joey Azofeifa

CEO, Arpeggio Bio

Download the Full Event Guide for Full Session Details.

Novel HTS Transcriptomics screen identifies initial NRF2 hit
Hit and Analog induces an interaction between NRF2 and BTrCP
Optimized analogs lead to significant in vivo activity in multiple lung cancer models with very favorable drug-like and safety profiles

12:00 pm Session Details to be Revealed

Michael Dabrowski

Chief Executive Officer, Pelago Bioscience

Download the Full Event Guide for Full Session Details.

12:30 pm Novel Highly Potent & Selective Molecular Glue Degrader of VAV1 for Autoimmune & Chronic Inflammatory Diseases

WU DU

Senior Vice President - Medicinal Chemistry, Hinova Pharmaceuticals

Download the Full Event Guide for Full Session Details.

VAV1 is a FIC target for autoimmune and chronic inflammatory diseases
Hinova discovers novel VAV1 degrader with high potency and selectivity
Achieved complete VAV1 degradation in vivo upon single oral dosing of VAV1 degrader

1:00 pm Lunch Break & Networking

Track A: Discovery Track B: Pre-Clinical Development Track C: Translational & Clinical Development

Track A: Discovery

Advancing Integrase Degraders & Decoding Cooperativity in Induced Proximity to Overcome Enable Potent, Orally Bioavailable & Safe Therapeutics

1:30 pm Developing an HIV Integrase Degrader to Unlock the Infectious Indication Landscape for Degraders

Guangdi Wang

Chief Scientific Officer, EndoTarget

Download the Full Event Guide for Full Session Details.

2:00 pm Panel Discussion: Cracking the Code: Understanding & Measuring Cooperativity in Induced Proximity Modalities

Rick Ewing

Vice President & Head of Chemistry, Rapafusyn Pharmaceuticals

Prakash Palde

Director - Biophysics, High Throughput Screening & Oncology, Pfizer

Sanjiv Shah

Exe, Revolution Medicines

Download the Full Event Guide for Full Session Details.

3:00 pm Session Details to be Revealed

Track B: Pre-Clinical Development

Pioneering Degraders to Unlock Epigenetic & Neurotrophic Targets & Transform Cancer & Pain Therapeutics

1:30 pm Advancing CNS Penetrant Degraders Through Emerging Design Principles to Cross the BBB

Chris Nasveschuk

Senior Vice-President of Chemical Sciences, C4 Therapeutics Inc

Download the Full Event Guide for Full Session Details.

What does the literature teach us about CNS drugs, including beyond rule of 5 drugs, with CNS exposure?
Current methods for CNS exposure and Kpuu determination
Heterobifunctional degraders that demonstrate CNS exposure

2:00 pm PROteolysis TArgeting Chimera (PROTAC) Degrader Molecules Selectively Clear Proteins that Cause Neurological Diseases

James Gregory

Associate Director, Exploratory Neuroscience, Arvinas, Inc.

Download the Full Event Guide for Full Session Details.

Progress in orally bioavailable, CNS-penetrant PROTAC degraders
Update on ARV-102 central target and pathway engagement
Exploring new PROTAC approaches to neurological diseases

2:30 pm PROteolysis TArgeting Chimera (PROTAC) Degrader Molecules Selectively Clear Proteins that Cause Neurological Diseases

Mark Noviski

Associate Director, Cell Biology & Project Lead, Nurix Therapeutics, Inc.

CNS malignancies and inflammatory diseases represent a challenging space for drug discovery due to the difficulty of delivering drugs to these privileged compartments
While degraders typically fall well outside the established chemical “rules” for predicting CNS penetration, Nurix’ approach to optimization has allowed us to develop a portfolio of CNSpenetrant degraders with demonstrated activity in animal models and in the clinic
Targeted protein degradation represents a powerful therapeutic strategy that can address privileged compartments, disrupt pathogenic scaffold functions and target previously undruggable proteins

Track C: Translational & Clinical Development

Driving Innovation in Targeted Degradation & RNA-Protein Drugging While Addressing Real-World Clinical Translation Challenges

1:30 pm Presenting the Journey to the Clinic for a Novel Bispecific Antibody EpiTAC that Selectively Degrades EGFR in Tumors

Shyra Gardai

Chief Scientific Officer, EpiBiologics

Download the Full Event Guide for Full Session Details.

2:00 pm Roundtable Discussion: From Bench to Bedside: What It Really Takes to Get TPD Therapies into the Clinic

Nan Ji

CEO, PAQ Therapeutics

Download the Full Event Guide for Full Session Details.

2:30 pm Strategies to Drug RNA-Protein Complexes with Small Molecules

Dominic Reynolds

Chief Scientific Officer, Remix Therapeutics

Download the Full Event Guide for Full Session Details.

3:00 pm Afternoon Break & Networking

Securing the Future of Induced Proximity with Pioneering Academic Breakthroughs & Emerging Biotech Pioneers Ready to Take 2026 by Storm

3:45 pm Harnessing Degradation to Achieve Selectivity & First-in-Class Targeting of Challenging Chromatin Regulatory Proteins

Steven Bellon

Chief Scientific Officer, Foghorn Therapeutics

Download the Full Event Guide for Full Session Details.

4:15 pm tPRIME: A Novel Induced Proximity Approach to Targeting p53-Y220C Mutant Cancers

Joshua Murtie

Vice President - Biology, Photys Therapeutics

Download the Full Event Guide for Full Session Details.

4:45 pm Chair’s Closing Remarks

5:00 pm End of Industry Day 2

Explore the Agenda

7:30 am Check-In & Morning Coffee

8:20 am Chair’s Opening Remarks

Navigating the Evolving TPD Landscape to Understand Future Directions & Drive the Next-Generation of Proximity Therapeutics

8:30 am Panel Discussion: The TPD Investment Landscape: Lessons from Deals in 2025 & Expectations for 2026

9:15 am Discovery of a VHL-Based Molecular Glue Degrader Targeting GEMIN3 Using Picowell RNA-Sequencing

9:45 am Illuminating New Insights in Targeted Protein Degradation Kinetics, Mechanisms, & Selectivity

10:15 am Expanding Targeted Glue Applications by Recruiting Novel E3 Ligases Across Diverse Targets

10:45 am Morning Break & Networking

Accelerating Molecular Glue Innovation Through Structure-Guided Design & Empirical Discovery to Enable Selective Targeting & Unlock New Therapeutic Opportunities

11:30 am Structure-Based Development of Non-Degrader Molecular Glues to Selectively Stabilize a Tumor Suppressor Phosphatase Complex

12:00 pm K-RAS Molecular Glue Degraders

12:30 pm Building A Computational Design Platform For Any Molecular Glue

1:00 pm Lunch Break & Networking

Advancing Integrase Degraders & Decoding Cooperativity in Induced Proximity to Overcome Enable Potent, Orally Bioavailable & Safe Therapeutics

1:30 pm Developing an HIV Integrase Degrader to Unlock the Infectious Indication Landscape for Degraders

2:00 pm Panel Discussion: Cracking the Code: Understanding & Measuring Cooperativity in Induced Proximity Modalities

3:00 pm Session Details to be Revealed

3:00 pm Afternoon Break & Networking

Securing the Future of Induced Proximity with Pioneering Academic Breakthroughs & Emerging Biotech Pioneers Ready to Take 2026 by Storm

3:45 pm Harnessing Degradation to Achieve Selectivity & First-in-Class Targeting of Challenging Chromatin Regulatory Proteins

4:15 pm tPRIME: A Novel Induced Proximity Approach to Targeting p53-Y220C Mutant Cancers

4:45 pm Chair’s Closing Remarks

5:00 pm End of Industry Day 2

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organized By